Natural product therapy for pulmonary arterial hypertension: 5,7-Dihydroxy-6-geranyl flavanone (DGF), isolated from Amorpha Fructicosa, inhibits the development of pulmonary arterial hypertension via down regulation of Notch3 and its target gene Hes-5, 26/June/2017, 10.36 pm

Natural product-derived therapy for glucose homeostasis and TIIDM: Sulforaphane, isolated from Broccoli, increases Barr2 expression, augments the functional activity of CAMKII, increases insulin secretion, promotes glucose homeostasis, prevents progression to TIIDM and ameliorates obesity-associated metabolic deficits via down regulation of its target gene, 25/June/2017, 11.42 pm
June 25, 2017
Natural product-derived Combination therapy for Squamous cell carcinoma of head and neck (HNSCC): A therapeutic mix encompassing an anticancer drug, 1,25-dihydroxyvitamin D and Artemisinin may decrease BMI1 and AP-1 expression, overcome chemotherapeutic resistance, promote chemosensitivity, suppress cancer stem cells in HNSCC, and inhibit lymph node metastasis via down regulation of its target genes, 26/June/2017, 10.56 pm
June 26, 2017
Show all

What they say: 

A study from the University of California, La Jolla, California, USA shows that Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published in the 15 November  2009 issue of the journalNature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054] by Prof. Thistlethwaite PA, Li X and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product therapy for pulmonary arterial hypertension:5,7-Dihydroxy-6-geranyl flavanone (DGF), isolated from Amorpha Fructicosa, inhibits the development of pulmonary arterial hypertension via down regulation of  Notch3 and its target gene Hes5


Significance of the study:  

5,7-Dihydroxy-6-geranyl flavanone (DGF), by increasing the expression of its target gene, it may decrease the expression of Notch3 and its target gene Hes-5 (Fig.1).  Thus, pharmacological formulations encompassing “5,7-Dihydroxy-6-geranyl flavanone (DGF) or its analog, either alone or in combination with other drugs” may be used to treat pulmonary arterial hypertension.[easy_payment currency=”USD”]

Figure 1. Mechanistic insights into how 5,7-Dihydroxy-6-geranyl flavanone (DGF) inhibits the development of pulmonary hypertension.


Details of the research findings:

Idea formulated by : Dr. L Boominathan PhD

Amount: $100#

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How 5,7-Dihydroxy-6-geranyl flavanone (DGF) inhibits Notch-3 expression

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References: 

Web: http://genomediscovery.org or http://newbioideas.com/

CitationBoominathan, L.,  Natural product therapy for pulmonary arterial hypertension:5,7-Dihydroxy-6-geranyl flavanone (DGF), isolated from Amorpha Fructicosa, inhibits the development of pulmonary arterial hypertension via down regulation of  Notch3 and its target gene Hes-5, 26/June/2017, 10.35 pm Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, drop us a line at info@genomediscovery.org

Comments are closed.